A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Study Phase: Phase 2
Recruitment Status: Recruiting
Start Date: March 05, 2024
End Date: July 23, 2027
Inclusion Criteria:
1. Male or female aged 18-75 years old with diagnosis of CD for at least 30 days.
2. Confirmed diagnosis of moderately to severely active CD assessed by SES-CD and CDAI.
3. Participants must have had an inadequate response to, loss of response to, or intolerance to at least one conventional or biologic therapy for CD.
4. Participants must meet the contraception recommendations.
Exclusion Criteria:
1. Participants with indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, and diverticular disease associated with colitis, and/or ulcerative colitis.
2. Have complications of CD that might require surgery during the study.
3. Participants with a current ostomy.
4. Participants who have failed 3 or more classes of advanced therapies.
-
Conditions:
- Crohn Disease